Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 4, 2016, Pages 733-743

  Gupta, Anubha ^a   Hussein, Ziad ^a   Hassan, Raffit ^c   Wustner, Jason ^b   Maltzman, Julia D ^b   Wallin, Bruce A ^b  

^a EISAI CO LTD   (Japan)

^b Morphotek Inc   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Amatuximab; Malignant pleural mesothelioma; Monoclonal antibody; Population pharmacokinetic pharmacodynamic modeling

Indexed keywords

AMATUXIMAB; CISPLATIN; GEMCITABINE; PEMETREXED; MONOCLONAL ANTIBODY; MORAB-009 MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PLEURAL NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MODELS, BIOLOGICAL; PLEURAL NEOPLASMS;

EID: 84959147343     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-2984-z     Document Type: Article

References (22)

1. Sugarbaker DJ, Garcia JP, Richards WG et al (1996) Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma - Results in 120 consecutive patients. Ann Surg 224:288-294
2. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644
3. Manzini VD, Brollo A, Franceschi S et al (1993) Prognostic factors of malignant mesothelioma of the pleura. Cancer 72:410-417
4. Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373-381
5. Ordonez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16:192-197
6. Hassan R, Laszik ZG, Lerner M et al (2005) Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124:838-845
7. Argani P, Iacobuzio-Donahue C, Ryu B et al (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862-3868
8. Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13:243-247
9. Miettinen M, Sarlomo-Rikala M (2003) Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 27:150-158
10. Hassan R, Schweizer C, Lu KF et al (2010) Inhibition of mesothelin-CA125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer 68:455-459
11. Kelly RJ, Sharon E, Pastan I, Hassan R (2012) Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 11:517-525
12. Hassan R, Ebel W, Routhier EL et al (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20
13. Hassan R, Cohen SJ, Phillips M et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132-6138
14. Hassan R, Jahan T, Kindler HL et al (2014) Amatuximab, a chimeric monoclonal antibody to mesothelin in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: results of a multi-center phase II clinical trial. Clin Cancer Res 20:5927-5936
15. Fujisaka Y, Kurata T, Tanaka K et al (2015) Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs 33:380-388
16. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504
17. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659
18. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17-20
19. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151
20. Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11:371-380
21. Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development - Part 2: introduction to pharmacokinetic modeling methods. Pharmacometrics & Systems Pharmacology, CPT, p e38. doi: 10.1038/psp.2013.14
22. Mould D, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies. Concepts and lessons for drug development. Biodrugs 24:23-39